Hematology, Neurology Star In Swan Song For The Office Of New Drugs’ Division Structure
Pink Sheet analysis of three years of novel US FDA approvals show the swiftest average time to approval in oncology, hematology, and antiviral divisions; neurology and hematology divisions contributed the most approvals.
You may also be interested in...
OND will grow to eight offices and 27 clinical divisions, which is slightly different than an early proposal.
Is it a problem that new drugs clear some review divisions faster than others? FDA analysis attributes differences to the proportion of applications qualifying for expedited review – a natural outgrowth of the priority placed on medical advances – not a management problem in need of a fix.
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.